01IN8bio (INAB) will report Q3 2026 earnings on November 5, 2026 after market close with expected EPS of -$0.38.
02The stock trades at $0.92 with a market capitalization of $8.0 million as a healthcare company.
03Analysts expect earnings per share to worsen compared to the prior year quarter's $0.00 result.
04Recent earnings showed improving performance, with Q2 beating estimates by 40.5% and Q1 by 61.2%.
Earnings Results
IN8bio, Inc. (NASDAQ:INAB) is scheduled to report its Q3 earnings results on November 05, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.38, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $0.92 with a market capitalization of $8.0M.
Ahead of IN8bio, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking IN8bio, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.